Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Pasithea Therapeutics宣布首批队列已完成其评估Ras、Nf1和Raf突变癌症Pas-004的1期试验的初始给药
Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Pasithea Therapeutics宣布首批队列已完成其评估Ras、Nf1和Raf突变癌症Pas-004的1期试验的初始给药
使用浏览器的分享功能,分享给你的好友吧